Unregulated Amanita muscaria sales threaten public health, study warns as consumers are misled by psilocybin-like marketing claims

A University of California San Diego team warns that unregulated sales of Amanita muscaria mushrooms pose public health risks, especially as consumer interest rises rapidly. The study links the market growth to marketing tactics that piggyback on the growing legitimacy of psilocybin research for depression. It notes that Amanita muscaria products are often sold as gummies or chocolates with vague or misleading health claims. Researchers emphasize that Amanita muscaria and psilocybin produce different psychotropic effects because their active compounds differ (mus cimol and ibotenic acid versus psilocybin). They also argue Amanita muscaria is potentially more toxic than several other drugs, while current labeling and regulatory oversight leave consumers with limited informed consent. The authors recommend either placing Amanita muscaria on the controlled substances list for evaluation or, if not scheduled, applying stricter consumer-safety measures like accurate dosing, childproof packaging, age limits, and clearer mental health guidance on distinguishing Amanita muscaria from psilocybin.